Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Hold" by Brokerages

Key Points

• Analysts maintain a “Hold” consensus on Xencor, with five buy, three hold and one sell rating among nine firms. The average 12-month price target is $24.86, while recent targets range from $14 to $44.
• Xencor shares opened at $20.00, up 0.8%, with a market capitalization of approximately $1.48 billion. The stock has traded between $6.92 and $21.96 over the past year.
• The biopharmaceutical company reported a quarterly loss of $0.29 per share, beating the consensus estimate for a $0.80 loss, while revenue of $51.22 million exceeded estimates of $18.89 million and rose 17.4% year over year.

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) has received an average recommendation of "Hold" from the nine ratings firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have given a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $24.8571.

Several brokerages have weighed in on XNCR. Cantor Fitzgerald boosted their price objective on Xencor from $43.00 to $44.00 and gave the stock an "overweight" rating in a report on Thursday. Wedbush upped their target price on shares of Xencor from $26.00 to $30.00 and gave the company an "outperform" rating in a research report on Thursday. Royal Bank Of Canada raised their target price on shares of Xencor from $19.00 to $20.00 and gave the company an "outperform" rating in a research note on Thursday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Xencor in a research report on Wednesday, June 24th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Xencor from $13.00 to $14.00 and gave the stock a "neutral" rating in a research note on Monday, May 11th.

Xencor Stock Up 0.8%

XNCR stock opened at $20.00 on Friday. The company has a market cap of $1.48 billion, a P/E ratio of -9.22 and a beta of 0.85. Xencor has a twelve month low of $6.92 and a twelve month high of $21.96. The business has a fifty day moving average of $15.52 and a 200-day moving average of $13.32.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.51. The business had revenue of $51.22 million for the quarter, compared to analyst estimates of $18.89 million. Xencor had a negative return on equity of 27.58% and a negative net margin of 155.59%.The firm's revenue for the quarter was up 17.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.41) earnings per share. As a group, equities research analysts anticipate that Xencor will post -3.76 earnings per share for the current fiscal year.

Institutional Trading of Xencor

Institutional investors and hedge funds have recently made changes to their positions in the business. BVF Inc. IL increased its holdings in Xencor by 160.3% in the fourth quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company's stock valued at $109,217,000 after purchasing an additional 4,393,579 shares during the last quarter. Legal & General Group Plc lifted its stake in Xencor by 603.7% in the third quarter. Legal & General Group Plc now owns 1,273,000 shares of the biopharmaceutical company's stock valued at $14,932,000 after buying an additional 1,092,095 shares during the period. State Street Corp boosted its holdings in Xencor by 22.7% during the fourth quarter. State Street Corp now owns 4,507,254 shares of the biopharmaceutical company's stock worth $69,006,000 after buying an additional 833,423 shares during the last quarter. Johnson & Johnson bought a new position in Xencor during the second quarter worth about $12,043,798,000. Finally, Jefferies Financial Group Inc. boosted its holdings in Xencor by 620.4% during the fourth quarter. Jefferies Financial Group Inc. now owns 720,440 shares of the biopharmaceutical company's stock worth $11,030,000 after buying an additional 620,440 shares during the last quarter.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor's research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source